Tonix Pharmaceuticals (NASDAQ:TNXP) Coverage Initiated at StockNews.com

Analysts at StockNews.com began coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a note issued to investors on Sunday. The brokerage set a “sell” rating on the stock.

Tonix Pharmaceuticals Trading Up 120.4 %

TNXP stock opened at $0.53 on Friday. Tonix Pharmaceuticals has a one year low of $0.12 and a one year high of $22.14. The company has a market capitalization of $99.05 million, a PE ratio of -0.01 and a beta of 2.23. The company’s 50 day moving average price is $0.18 and its two-hundred day moving average price is $0.56. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The business had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. As a group, analysts predict that Tonix Pharmaceuticals will post -17.63 earnings per share for the current fiscal year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.